Clinical trials: Abuse Tobacco
- Condition Abuse Tobacco
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Tobacco Use
Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes
This study is designed to evaluate the abuse liability of very low nicotine cigarettes compared to nicotine gum and usual brand cigarettes
- Trial name
- NCT03559751
- Testing
- VLN cigarettes (A), Usual Brand Cigarettes (B), Nicotine gum (C)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- 22nd Century Group, Inc.
Tobacco Use Disorder
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking.
- Trial name
- NCT02688374
- Testing
- Treatment A: Nicorette 2 mg coated mint gum, Treatment B: Nicotinell 2 mg coated mint gum, Treatment C: Nicotinell 2 mg coated fruit flavor gum
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tobacco Use Disorder, Smoking
A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge
This is a study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.
- Trial name
- NCT01336816
- Testing
- Ariva Silver Wintergreen
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Star Scientific, Inc
Tobacco Use, Nicotine Dependence, Other Tobacco Product
A Study to Characterize Puff Topography With Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers
A Study to Characterize Puff Topography with Use of a JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers
- Conditions
- Tobacco Use, Nicotine Dependence, Other Tobacco Product, Tobacco Smoking
- Trial name
- NCT03596034
- Testing
- JUUL 5%, Virginia Tobacco, ENDS product
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Smoking, Tobacco Use
CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches
This is a two-site, open-label, randomized, 5-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake…
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05129657
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Nicotine Dependence, Cigarettes
Evaluation of LLLT/Music for Smoking Cessation
The purpose of this research is to study the preliminary effectiveness of a light therapy and music device for at-home use to aid the seasoned cigarette smoker in his/her attempt to stop smoking.
- Trial name
- NCT04830384
- Testing
- Fully Active, LLLT Only, Music Only
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Freedom Laser, Inc.
Smoking, Tobacco Use Disorder
QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions
QuitAdvisorMD: A point-of-care tool for brief smoking cessation interventions Under a Phase II SBIR grant supported by NIH/NIDA, we are developing QUITAdvisorMD: a point-of-care, patient-centered resource for counseling patients…
- Trial name
- NCT01065493
- Testing
- QuitAdvisorMD Software Algorithm, Standard Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Silverchair Science & Communications, LLC
Smoking Behaviors, Smoking ( Cigarette)
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
This will be a randomized, open-label, 2-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking Behaviors, Smoking ( Cigarette), Tobacco Use, Abuse Liability
- Trial name
- NCT07881848
- Testing
- Menthol 5%, Combustible cigarette
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Cigarette Smoking
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
To better understand the PK and associated pharmacodynamic (PD) responses produced by the Research ENDS S-TA-U001 product, this study will compare the Research ENDS S-TA-U001 to The subject's own brand combustion (non-menthol)…
- Trial name
- NCT02792426
- Testing
- Research ENDS S-TA-U001, Nicorette Inhalator
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NJOY, Inc.
Smoking Cessation, Tobacco Use Disorder
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an…
- Trial name
- NCT04868253
- Testing
- EMB-01
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Tobacco Use Disorder, Smoking
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
Study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.
- Trial name
- NCT01337817
- Testing
- Ariva Silver Wintergreen, Ariva Wintergreen
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Star Scientific, Inc
Smoking, Smoking Behaviors
CSD201201: Study to Assess Elements of Abuse Liability for Electronic Nicotine Delivery System P12
This is a randomized, open-label, 6-way crossover, multi-site study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]), and nicotine uptake…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05210699
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Nicotine Dependence, Nicotine Dependence, Cigarettes
Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers
A Ten Sequence, Open Label, Randomized Crossover Study Comparing Nicotine Pharmacokinetics of JUUL 1.7% and JUUL 5% Nicotine Salt Based ENDS Products, in Healthy Adult Smokers.
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- NCT03593239
- Testing
- Tobacco flavored JUUL 1.7% ENDS, Tobacco flavored JUUL 5% ENDS, Mint flavored JUUL 1.7% ENDS
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Smoking Cessation, Nicotine Dependence
Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy
CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind, placebo-controlled Phase II clinical trial. The main objectives are to select the most efficient dose and to assess long-term efficacy of NFL-101…
- Trial name
- CESTO2 (NCT04571216)
- Testing
- NFL-101 dose 1, NFL-101 dose 2
- Where
- 9 sites in France
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- NFL Biosciences SAS
Smoking, Smoking Behaviors
Abuse Liability for Eight Electronic Nicotine Products
This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07323511
- Testing
- Product A, Product B, Product C
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco Use
Modern Nicotine Oral Product Abuse Liability
This is a two-site, open-label, randomized, 8-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake…
- Trial name
- NCT06777784
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Healthy Smokers
Nicotine Patch - Bioequivalence Study
The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine patch to that of a reference formulation following repeated applications
- Trial name
- NCT02089308
- Testing
- Test treatment : V0116 transdermal patch, Reference treatment : Nicotine transdermal patch
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Tobacco Use Disorder
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
The purpose of this study is to assess the bioequivalence of the 21mg nicotine transdermal patch from GSK Dungarvan (Test) compared to the 21mg nicotine transdermal patch currently manufactured by Alza (Reference).
- Trial name
- NCT05024747
- Testing
- NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- HALEON
Smoking, Tobacco Smoking
CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems
This is a randomized, open-label, crossover study designed to evaluate elements of abuse liability (AL) including subjective effects, plasma nicotine uptake, and physiological measures during and following ad libitum use of the…
- Conditions
- Smoking, Tobacco Smoking, Tobacco Use
- Trial name
- NCT04094363
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- RAI Services Company